Related Experiment Videos
HEC-1 cells
Hiroyuki Kurarmoto1, Mieko Hamano, Manami Imai
1Department of Clinical Cytology Graduate School of Medical Sciences, School of Medicine, Kitasato University, Sagamihara, Kanagawa, Japan. kuramoto@cc.ahs.kitasato-u.ac.jp
Human Cell
|September 14, 2002
Summary
The HEC-1 cell line, the first of its kind for human endometrial adenocarcinoma, provides a stable in vitro model for studying endometrial cancer. This research details its establishment and characterization, highlighting its utility in cell and molecular biology research.
Area of Science:
- Oncology
- Cell Biology
- Gynecologic Pathology
Background:
- The development of reliable in vitro models is crucial for advancing cancer research.
- Human endometrial adenocarcinoma presents unique challenges for in vitro study.
- The HEC-1 cell line was established to address the need for a specific model of endometrial carcinoma.
Purpose of the Study:
- To report the establishment and characterization of the HEC-1 cell line.
- To demonstrate the utility of the HEC-1 cell line for endometrial carcinoma research.
- To provide a foundation for future cell and molecular biological studies on endometrial cancer.
Main Methods:
- Establishment of the HEC-1 cell line from human endometrial adenocarcinoma.
- Characterization of the HEC-1 cell line to meet proposed requirements.
- Review of existing literature and previously obtained results using HEC-1 cells.
Main Results:
- The HEC-1 cell line was successfully established and characterized.
- The cell line meets the necessary criteria for a stable experimental system.
- Previous studies demonstrate the HEC-1 cell line's applicability in endometrial cancer research.
Conclusions:
- The HEC-1 cell line serves as a valuable and stable in vitro model for human endometrial adenocarcinoma.
- Its establishment and characterization facilitate cell and molecular biological research on endometrial carcinoma.
- The HEC-1 cell line has proven useful for advancing the understanding and study of endometrial cancer.